India, April 30 -- This week's biotech landscape witnessed regulatory approvals in the US and Europe, acquisitions, and a few trial halts, alongside positive data readouts spanning multiple therapeutic areas, including Type 1 Diabetes, Male Pattern Hair Loss, and Hereditary angioedema.
Let's unpack the specifics.
FDA and EU Approvals & Rejections
Crinetics - EC Clears PALSONIFY for Acromegaly
Crinetics Pharmaceuticals, Inc. (CRNX) received European Commission approval for PALSONIFY to treat adults with acromegaly, expanding its reach beyond last year's U.S. approval. The decision covers all 27 EU member states and three EEA countries, supported by positive data from the Phase 3 PATHFNDR-1 and PATHFNDR-2 trials. PALSONIFY becomes the fir...